Comparative Pharmacology
Head-to-head clinical analysis: AMINOCAPROIC ACID versus NUMBRINO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOCAPROIC ACID versus NUMBRINO.
AMINOCAPROIC ACID vs NUMBRINO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation, reducing fibrinolysis by binding to plasminogen and blocking its conversion to plasmin.
Selective serotonin reuptake inhibitor (SSRI); increases synaptic serotonin by inhibiting SERT.
Loading dose: 4-5 g intravenously (IV) over 1 hour, followed by continuous IV infusion of 1 g/hour for 8 hours or until bleeding controlled. Oral: 1 g every hour for 8 hours, then 1 g every 2 hours for 8 additional hours.
2 mg/kg intravenously every 8 hours, max 150 mg per dose.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1-3 hours) in patients with normal renal function. Prolonged in renal impairment (up to 20 hours in anuria).
Clinical Note
moderateAminocaproic acid + Tretinoin
"Aminocaproic acid may increase the thrombogenic activities of Tretinoin."
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min)
Primarily renal (80-90% unchanged). A small fraction (<5%) is excreted as metabolites. No significant biliary/fecal elimination.
Renal: 70% unchanged; hepatic metabolism: 20%; fecal: 10%
Category C
Category C
Antifibrinolytic
Antifibrinolytic